Unknown

Dataset Information

0

Functional recovery of a novel knockin mouse model of dysferlinopathy by readthrough of nonsense mutation.


ABSTRACT: Biallelic mutations in the dysferlin gene cause limb-girdle muscular dystrophy 2B or Miyoshi distal myopathy. We found that nonsense mutations are the most common mutation type among Korean patients with dysferlinopathy; more than half of the patients have at least one nonsense allele, which may be amenable to readthrough therapy. We generated a knockin mouse, dqx, harboring DYSF p.Q832∗ mutation. Homozygous dqx mice lacked dysferlin in skeletal muscle, while 2 weeks of oral ataluren restored dysferlin expression and ameliorated skeletal muscle pathology. Their physical performance improved, and protection against eccentric contractions was noted. The improvement was most evident in mice treated with oral ataluren of 0.9 mg/mL. These improvements were sustained for 8 weeks in ataluren-treated dqx mice, while the parameters of A/J mice treated with ataluren over the same period did not improve. These results support that readthrough therapy by oral ataluren may also be applicable to dysferlinopathy patients with nonsense mutation.

SUBMITTER: Seo K 

PROVIDER: S-EPMC8181533 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Functional recovery of a novel knockin mouse model of dysferlinopathy by readthrough of nonsense mutation.

Seo Kyowon K   Kim Eun Kyoung EK   Choi Jaeil J   Kim Dae-Seong DS   Shin Jin-Hong JH  

Molecular therapy. Methods & clinical development 20210501


Biallelic mutations in the dysferlin gene cause limb-girdle muscular dystrophy 2B or Miyoshi distal myopathy. We found that nonsense mutations are the most common mutation type among Korean patients with dysferlinopathy; more than half of the patients have at least one nonsense allele, which may be amenable to readthrough therapy. We generated a knockin mouse, <i>dqx</i>, harboring <i>DYSF</i> p.Q832∗ mutation. Homozygous <i>dqx</i> mice lacked dysferlin in skeletal muscle, while 2 weeks of oral  ...[more]

Similar Datasets

| S-EPMC10216094 | biostudies-literature
| S-EPMC7216799 | biostudies-literature
| S-EPMC6048497 | biostudies-literature
| S-EPMC8601662 | biostudies-literature
| S-EPMC8086047 | biostudies-literature
| S-EPMC9273842 | biostudies-literature
| S-EPMC11465179 | biostudies-literature
| S-EPMC8436412 | biostudies-literature
| S-EPMC10258827 | biostudies-literature
| S-EPMC11638873 | biostudies-literature